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Abstract
Background: Isometheptene is a sympathomimetic drug effective in acute migraine treatment. It is composed of two
enantiomers with diverse pharmacological properties. This study investigated in pithed rats the cardiovascular effects of
(S)- isometheptene and (R)-isometheptene, and the pharmacological profile of the more potent enantiomer.
Methods: The effects of i.v. bolus injections (0.03, 0.1, 0.3, 1 and 3 mg/kg) of isometheptene racemate, (S)-isometheptene
or (R)-isometheptene on heart rate and blood pressure were analyzed in control experiments. The enantiomer producing
more pronounced tachycardic and/or vasopressor responses was further analyzed in rats receiving i.v. injections of
prazosin (0.1 mg/kg), rauwolscine (0.3 mg/kg), propranolol (1 mg/kg) or intraperitoneal reserpine (5 mg/kg, -24 h).
Results: Compared to (R)-isometheptene, (S)-isometheptene produced greater vasopressor responses, whilst both
compounds equipotently increased heart rate. The tachycardic responses to (S)-isometheptene were abolished after
propranolol, but remained unaffected by the other antagonists. In contrast, the vasopressor responses to (S)-
isometheptene were practically abolished after prazosin. Interestingly, after reserpine, the tachycardic responses to
(S)-isometheptene were abolished, whereas its vasopressor responses were attenuated and subsequently abolished
by prazosin.
Conclusions: The different cardiovascular effects of the isometheptene enantiomers are probably due to differences in
their mechanism of action, namely: (i) a mixed sympathomimetic action for (S)-isometheptene (a tyramine-like action
and a direct stimulation of α1-adrenoceptors); and (ii) exclusively a tyramine like action for (R)-isometheptene. Thus,
(R)-isometheptene may represent a superior therapeutic benefit as an antimigraine agent.
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Background
Isometheptene racemate is a sympathomimetic amine
that has been used for decades in the acute treatment of
moderate primary headaches (i.e. migraine and tension-
type headaches) [1, 2], but its exact mechanisms of
action have not been comprehensively explored. In this
respect, our group has demonstrated in pithed rats [3]
and anesthetized dogs [4] that isometheptene racemate
behaves as a dual-acting sympathomimetic agent produ-
cing: (i) an indirect vasoconstrictor tyramine-like action
(attenuated by reserpine) that involves the displacement
of endogenous noradrenaline from sympathetic nerves;
and (ii) a direct vasoconstriction that results in either rat
vasopressor responses mediated by α1-adrenoceptors [3]
or decreases in canine external carotid blood flow/con-
ductance mediated by α2A/2C-adrenoceptors [4]. These
properties have linked isometheptene’s therapeutic
effectiveness with the vascular theory of migraine [5], so
that its cranial vasoconstriction may reduce the
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phenomenon (i.e. vasodilatation) that has been advocated
as a mechanism of headache and associated symptoms
[6]. Interestingly, sumatriptan (a 5-HT1B/1D receptor agon-
ist with acute antimigraine properties) seems to exert part
of its antinociceptive action by constricting the human
middle meningeal artery (MMA) [7, 8]. In contrast,
isometheptene racemate failed to constrict the porcine
MMA [9], but the fact that it produces severe arterial
vasospasm [10, 11] supports its vasoactive action on
dilated cranial and cerebral arterioles [12, 13].
Tonix Pharmaceuticals has separated isometheptene
racemate into its two enantiomers (R)-isometheptene
and (S)-isometheptene, in order to explore their efficacy
in the acute treatment of primary headaches [14]. Iso-
metheptene racemate binds with high affinity (Ki = 42
nM) to the I1-imidazoline receptor (I1-R), suggesting that
this receptor, along with α-adrenoceptors, could be
involved in its antimigraine action [15]. Moreover, (R)-
isometheptene binds to the I1-R (Ki = 18 nM) with about
60-fold greater affinity than (S)-isometheptene (Ki =
1100 nM) [15]. Notably, other studies have described: (i)
a decreased pain threshold in I1-R knockout mice [16];
and (ii) that treatment with (R)-isometheptene relieved
trigeminal sensitivity in the inflammatory soup and in
spontaneous trigeminal allodynia rat models, two differ-
ent models of chronic migraine [17]. This study investi-
gated the cardiovascular effects produced by these novel
compounds in an experimental model predictive of
systemic (cardio) vascular side effects.
Methods
Animals
Seventy-four male normotensive Wistar rats (250–300 g,
8–10 weeks of age) were maintained at a 12/12-h light–
dark cycle (with light beginning at 07:00 h) and housed
in a special room at a constant temperature (22 ± 2 °C)
and humidity (50%), with food and water ad libitum in
their cages. All animal protocols of this investigation
were approved by our Institutional Ethics Committee
(CICUAL-Cinvestav; permission protocol number 507–
12) and followed the regulations established by the
Mexican Official Norm (NOM-062-ZOO-1999), in
accordance with ARRIVE (Animal Research: Reporting
In Vivo Experiments) reporting guidelines for the care
and use of laboratory animals.
General methods
After anaesthesia with sodium pentobarbital (60 mg/kg,
i.p.) and cannulation of the trachea, all rats were pithed
by inserting a stainless steel rod through the orbit and
foramen magnum and down the vertebral foramen, as
previously reported [18, 19]. The animals were then
artificially ventilated with room air using a model 7025
Ugo Basile pump (56 strokes/min.; stroke volume:
20 ml/kg), as previously established [20]. After cervical
bilateral vagotomy, catheters were placed in: (i) the right
femoral vein, for the administration of antagonists,
isometheptene racemate, (R)-isometheptene or (S)-iso-
metheptene; and (ii) the left carotid artery, connected to
a Grass pressure transducer (P23XL), for the recording
of arterial blood pressure. Heart rate was measured with
a tachograph (7P4F, Grass Instrument Co., Quincy, MA,
USA) triggered from the blood pressure signal. Both
heart rate and blood pressure were recorded simultan-
eously by a model 7D Grass polygraph (Grass Instrument
Co., Quincy, MA, USA). The body temperature of each
pithed rat was maintained at 37 °C by a lamp and moni-
tored with a rectal thermometer.
Experimental protocols
After a stable hemodynamic condition during at least
30 min, baseline values of heart rate and diastolic blood
pressure (a more accurate indicator of peripheral
vascular resistance than mean blood pressure) were de-
termined. Subsequently, the 74 rats were randomly
assigned into three main sets (n = 24, 40 and 10) for
performing the following dose–response protocols. We a
priori decided to investigate the pharmacological charac-
teristics of the responses to the most potent enantiomer
in more detail, since this enantiomer would most likely
be responsible for the side-effects induced by isomethep-
tene. In addition, we planned to study for the least
potent enantiomer to which extent the cardiovascular
responses were mediated by a direct or indirect,
tyramine-like, mechanism of action.
Protocol I. Comparative analysis of the effects produced
by the isometheptene enantiomers
The first set of animals (n = 24) was divided into four
groups (n = 6 each) that received consecutive i.v. bolus
injections (0.03, 0.1, 0.3, 1 and 3 mg/kg) of, respectively:
(i) isometheptene racemate; (ii) (S)-isometheptene; (iii)
(R)-isometheptene; and (iv) equivalent volumes of
physiological saline (1 ml/kg given 5 consecutive times;
vehicle for dissolving isometheptene). The peak effects
produced by each dose of the above compounds on
heart rate and diastolic blood pressure were measured
and compared, as previously reported [3]. The dose-
intervals between the different doses of isometheptene
(racemate and enantiomers) ranged between 5 and
15 min, as in each case we waited with the administra-
tion of the next dose until heart rate and diastolic blood
pressure had returned to baseline values.
Protocol II. Analysis of the pharmacological profile of the
more potent enantiomer
The second set of animals (n = 40) was divided into
three subsets (n = 25, 10 and 5). The first subset
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(untreated; n = 25) received consecutive i.v. bolus injec-
tions of the more potent isometheptene enantiomer
(0.03, 0.1, 0.3, 1 and 3 mg/kg). Then, this subset was
divided into five groups (n = 5 each) that received i.v.
bolus injections of, respectively: (i) physiological saline
(1 ml/kg; vehicle for dissolving the antagonists); (ii)
prazosin (0.1 mg/kg; α1-adrenoceptor antagonist); (iii)
rauwolscine (0.3 mg/kg; α2-adrenoceptor antagonist);
(iv) the combination of prazosin (0.1 mg/kg) plus
rauwolscine (0.3 mg/kg); and (v) propranolol (1 mg/kg;
nonselective β-adrenoceptor antagonist). The doses of
the antagonists used were sufficient to completely block
their corresponding receptors, as previously reported
[3]. Subsequently, the responses to the above doses of
the isometheptene enantiomer were elicited again
15 min after administration of the aforementioned
compounds.
The second subset (reserpinized; n = 10) was pre-
treated with reserpine (5 mg/kg, i.p.) 24 h before the
start of the experiments, as previously reported by our
group [3], in order to eliminate the potential tyramine-
like action exerted by the more potent isometheptene
enantiomer. Then, this subset received sequential i.v.
bolus injections of the isometheptene enantiomer (0.03-
3 mg/kg) and was subsequently divided into two groups
(n = 5 each) that were given i.v. bolus injections of,
respectively: (i) physiological saline (1 ml/kg); and (ii) pra-
zosin (0.1 mg/kg). After 15 min, the responses to the above
isometheptene enantiomer doses were elicited again.
The third subset (sham; n = 5) was pretreated with the
vehicle of reserpine (1 ml/kg of 5% ascorbic acid; i.p.)
24 h before the start of the experiments. Then, this
subset received i.v. bolus injections of the isometheptene
enantiomer as previously described.
Protocol III. Effects of reserpine pretreatment on the
effects of the less potent enantiomer
Finally, the third set of animals (n = 10) was divided into
two groups (n = 5 each) that were pretreated i.p. (24 h
before the start of the experiments) with, respectively: (i)
1 ml/kg of 5% ascorbic acid; and (ii) 5 mg/kg reserpine.
Then, both groups received sequential i.v. bolus
injections of the less potent isometheptene enantiomer
(0.03-3 mg/kg).
Data presentation and statistical evaluation
The number of animals was justified by statistical power
calculation based on our previous studies with similar
methodology [3]. All data in the text and figures are
presented as mean ± S.E.M. The peak changes in the
baseline values of heart rate and diastolic blood pressure
elicited by the administration of isometheptene (racem-
ate and enantiomers) were determined. The difference
between the tachycardic and vasopressor responses to
isometheptene within one subset/group of animals as
well as between two groups (i.e. the more potent
isometheptene enantiomer in reserpine- and vehicle-
pretreated animals) were evaluated with the Student-
Newman-Keuls’ test, once a two-way repeated measures
analysis of variance had revealed that the samples repre-
sented different populations. Statistical significance was
accepted at P < 0.05.
Drugs
Apart from the anaesthetic (sodium pentobarbital), the
drugs used in the present study were: isometheptene
racemate (Carnick Laboratories, Cedar Knolls, NJ, USA);
(R)-isometheptene and (S)-isometheptene (Tonix Phar-
maceuticals Inc., New York, NY, USA); prazosin hydro-
chloride, rauwolscine hydrochloride, propranolol
hydrochloride and reserpine (Sigma Chemical Co., St.
Louis, MO, USA) All compounds were dissolved in
physiological saline with the exception of reserpine, which
was dissolved in 5% (w/v) ascorbic acid. A short period of
heating was needed to dissolve prazosin. These vehicles
had no significant effects on baseline heart rate or dia-
stolic blood pressure, as previously reported by our group
[3]. The doses mentioned in the text refer to the free base
of substances in all cases.
Results
Systemic hemodynamic variables
The baseline values of heart rate and diastolic blood
pressure in the pithed rats without reserpine were 260 ±
6 beats/min and 64 ± 1 mmHg, respectively. These
variables did not significantly differ (P > 0.05) from those
obtained in the animals pretreated with reserpine, i.e.
269 ± 4 beats/min and 67 ± 2 mmHg. Moreover, these
hemodynamic variables remained without significant
changes (P > 0.05) after administration of the i.v. bolus
injections of saline, prazosin, rauwolscine, the combin-
ation prazosin plus rauwolscine or propranolol (not
shown), as previously reported [3].
Effects of isometheptene enantiomers on heart rate and
diastolic blood pressure
Figure 1 shows the effects produced by i.v. administra-
tion of isometheptene racemate, (R)-isometheptene and
(S)-isometheptene on heart rate and diastolic blood
pressure. These compounds produced: (i) dose-dependent
tachycardic responses (left panel), with 3 mg/kg of these
compounds representing the effects of a supramaximal
dose; and (ii) dose-dependent vasopressor responses in
the case of isometheptene racemate and (S)-isomethep-
tene, while only smaller vasopressor responses (not dose--
dependent; P < 0.05 vs. the corresponding dose of saline)
were produced by the last two doses of (R)-
isometheptene.
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Effect of antagonists on (S)-isometheptene-induced
tachycardic and vasopressor responses
Figure 2 illustrates the tachycardic responses produced
by (S)-isometheptene before and after different treat-
ments. Indeed, these responses appeared to be tachyphy-
lactic as they were significantly attenuated (P < 0.05) in
control animals when repeating the dose-response curve
after 1 ml/kg physiological saline (Fig. 2a). Furthermore,
as compared to the tachycardic responses to (S)-iso-
metheptene produced after saline, these responses were
practically abolished after 1 mg/kg propranolol (Fig. 2e),
but remained unaffected after administration of the
other compounds (Figs. 2b, c, d).
In contrast, as shown in Fig. 3, the vasopressor re-
sponses to (S)-isometheptene were: (i) reproducible as
they remained practically unchanged after 1 ml/kg sa-
line (Fig. 3a); (ii) similarly and markedly blocked (P <
0.05) after 0.1 mg/kg prazosin (Fig. 3b) or the com-
bination of 0.1 mg/kg prazosin plus 0.3 mg/kg
rauwolscine (Fig. 3d); and (ii) unaffected (P > 0.05)
after 0.3 mg/kg rauwolscine (Fig. 3c) or 1 mg/kg
propranolol (Fig. 3e). It is noteworthy that the block-
ade produced by the combination of prazosin plus
rauwolscine did not significantly differ (P > 0.05) from
that produced by prazosin alone.
Cardiovascular effects of (S)-isometheptene in rats
pretreated i.p. with reserpine or its vehicle
Figure 4 shows the effects of i.p. pretreatment with
vehicle (5% ascorbic acid; 1 ml/kg), reserpine (5 mg/kg),
reserpine followed by i.v. saline (1 ml/kg) or reserpine
followed by i.v. prazosin (Praz; 0.1 mg/kg) on the
increases in heart rate and diastolic blood pressure
produced by (S)-isometheptene. Hence, in the vehicle-pre-
treated animals, (S)-isometheptene produced dose-de-
pendent increases in heart rate (Figs. 4a, b) and
diastolic blood pressure (Figs. 4c,d) as described
above. In contrast, in the reserpine-pretreated
animals: (i) (S)-isometheptene-induced tachycardic re-
sponses were practically abolished (as compared to
the respective responses in vehicle-pretreated animals;
P < 0.05), and the subsequent administration of saline
(Fig. 4a) or prazosin (Fig. 4b) produced no further
effect; and (ii) (S)-isometheptene-induced vasopressor
responses were significantly attenuated (P < 0.05, but
not abolished) and the subsequent administration of
saline produced no further effect (Fig. 4c), but the
subsequent administration of prazosin abolished these
responses (P < 0.05; Fig. 4d).
Fig. 1 Effects of i.v. bolus injections of isometheptene enantiomers
(0.03-3 mg/kg) or saline (1 ml/kg, given 5 times) on (a) heart rate;
and (b) diastolic blood pressure (DBP) in pithed rats. Full symbols
represent significant differences (P < 0.05) vs saline (vehicle). *P < 0.05
vs. the corresponding dose to (R)-isometheptene; n = 6 for
each group
Fig. 2 Effects of i.v. bolus injections of: (a) saline; (b) prazosin (Praz); (c) rauwolscine (Rauw); (d) the combination of Praz plus Rauw; or (e) propranolol
(Prop) on the increases in heart rate (Δ Heart rate) produced by (S)-isometheptene (0.03-3 mg/kg, i.v.) in pithed rats. *P < 0.05 vs. the corresponding
dose in the control curve; #P < 0.05 vs. the corresponding dose in the curve obtained after saline; n = 5 for each group
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Cardiovascular effects of (R)-isometheptene in rats
pretreated i.p. with reserpine or its vehicle
As shown in Fig. 5, in the animals pretreated with
vehicle (5% w/v ascorbic acid, 1 ml/kg; i.p.), (R)-iso-
metheptene induced dose-dependent tachycardic responses
(Fig. 5a) and small vasopressor responses (not dose-
dependent; Fig. 5b). In contrast, in the animals pretreated
with reserpine (5 mg/kg; i.p.), these tachycardic and
vasopressor responses were practically abolished (P < 0.05
when compared to those produced by the corresponding
dose in the vehicle curve).
Discussion
General
Apart from the implications discussed below, our study
demonstrates the importance of investigating separately
the enantiomers of a given compound. Indeed, the (R)-
and (S)-enantiomers of a racemate may behave pharma-
cologically different from each other [21]. Thus, it is
appropriate to consider each enantiomer as a separate
pharmacological entity with different properties, unless
proven otherwise [21]. In our study, the enantiomers of
isometheptene displayed clear pharmacodynamic differ-
ences in their cardiovascular effects, and these differences
could lead to the future usage of these enantiomers in
different conditions.
Systemic hemodynamic effects produced by the different
treatments in pithed rats
The fact that the baseline values of diastolic blood pres-
sure and heart rate remained without significant changes
after prazosin, rauwolscine, the combination prazosin
plus rauwolscine or propranolol (not shown), as previ-
ously reported [3], may be due to the fact that pithed
rats are devoid of central and peripheral nervous
Fig. 3 Effects of i.v. bolus injections of: (a) saline; (b) prazosin (Praz); (c) rauwolscine (Rauw); (d) the combination of Praz plus Rauw; or (e) propranolol
(Prop) on the increases in diastolic blood pressure (Δ DBP) produced by (S)-isometheptene (0.03-3 mg/kg, i.v.) in pithed rats. *P < 0.05 vs. the
corresponding dose in the control curve; n = 5 for each group
Fig. 4 Effects of i.p. pretreatment with vehicle (5% ascorbic acid),
reserpine (Reserp), reserpine followed by i.v. administration of
saline or reserpine followed by i.v. administration of prazosin
(Praz) on the increases in (a, b) heart rate (Δ Heart rate; upper
panel) and (c, d) diastolic blood pressure (Δ DBP; lower panel)
produced by (S)-isometheptene (0.03-3 mg/kg, i.v.) in pithed rats.
*P < 0.05 vs. the corresponding dose in the vehicle curve; #P < 0.05 vs.
the corresponding dose in the reserpine curve; n = 5 for each group
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influences. On this basis, it is most likely that the effect
of any of these antagonists on the tachycardic and
vasopressor responses to the isometheptene enantiomers
involves a direct interaction with their corresponding
receptors.
Differential cardiovascular effects of the isometheptene
enantiomers
In agreement with the sympathomimetic properties of
isometheptene racemate in pithed rats [3], both enan-
tiomers and the racemate produced dose-dependent
increases in heart rate, although the tachycardic
response produced by 3 mg/kg was not strictly dose-
dependent (Fig. 1a) and apparently tachyphylactic.
This finding implies a tyramine-like action (see
below), as previously reported [3], and that such a
high dose was supramaximal.
In contrast, (R)-isometheptene produced only small
vasopressor responses at 1 and 3 mg/kg (which were
not dose-dependent), while (S)-isometheptene and
isometheptene racemate produced dose-dependent
(and equipotent) vasopressor responses (Fig. 1b). The
simplest interpretation of these findings indicates: (i)
a differential pharmacological profile between (R)-iso-
metheptene and (S)-isometheptene; and (ii) that the
vasopressor effects of isometheptene racemate are
mostly mediated by the (S)-enantiomer (see below).
Since, overall, (S)-isometheptene displayed a higher
potency to produce cardiovascular responses, we
proceeded to analyse, in the first instance, the
pharmacological profile of the receptors/mechanisms
involved in the responses to (S)-isometheptene.
The role of a tyramine-like action producing indirect
stimulation of cardiac β-adrenoceptors in the tachycardic
responses to (S)-isometheptene
The tachycardic responses to isometheptene racemate in
pithed rats are mediated by an indirect tyramine-like
action involving stimulation of propranolol-sensitive β-
adrenoceptors, most likely of the β1-subtype [3]. In
keeping with this finding, the tachycardic responses
produced by (S)-isometheptene: (i) were highly tachy-
phylactic as they were not reproducible when repeating
a second dose–response after saline (Fig. 2a); (ii) are
mainly mediated by activation of propranolol sensitive
β-adrenoceptors (Fig. 2e); and (iii) do not involve activa-
tion of prazosin-sensitive α1-adrenoceptors and/or
rauwolscine-sensitive α2-adrenoceptors (Figs. 2b,c,d).
Most notably, the fact that these responses were practic-
ally abolished after reserpine (Fig. 4a) reinforces the role
of an indirect tyramine-like action in (S)-isometheptene-
induced tachycardic responses (i.e. by displacing
noradrenaline from sympathetic nerves which, in turn,
would subsequently stimulate cardiac β-adrenoceptors). It
is noteworthy that this dose-schedule with reserpine (i.e.
5 mg/kg, i.p.; −24 h) has been shown to abolish in pithed
rats the tachycardic and vasopressor responses to the
typical indirect sympathomimetic agent, tyramine [3].
The role of both an indirect tyramine-like action and a
direct stimulation of α1-adrenoceptors in the vasopressor
responses to (S)-isometheptene
Unlike its tachycardic responses (see above), the
vasopressor responses to (S)-isometheptene: (i) were re-
producible as they remained without significant changes
after saline (Fig. 3a); and (ii) are mainly mediated by
α1-adrenoceptors as these responses were markedly
blocked after prazosin (Fig. 3b), but not (P > 0.05) after
rauwolscine (Fig. 3c) or propranolol (Fig. 3e) in doses
high enough to completely block their respective recep-
tors mediating cardiovascular responses [3]. Consistent
with this suggestion, the combination prazosin plus
rauwolscine produced a blockade (Fig. 3d) that did not
significantly differ (P > 0.05) from that produced by
prazosin alone (Fig. 3b). Furthermore, the fact that reser-
pine markedly attenuated (but did not abolish) these
vasopressor responses (Fig. 4c), and that the subsequent
administration of prazosin practically abolished these
responses (Fig. 4d) suggests the involvement of a mixed
effect of (S)-isometheptene, namely: (i) a major indirect
(tyramine-like) mechanism; and (ii) a minor direct
sympathomimetic mechanism mediated by stimulation
of α1-adrenoceptors. In keeping with these findings, and
as implied by other studies at the neuro-vascular
junction [3, 22, 23]: (i) neuronally-displaced noradrenaline
(i.e. by a tyramine-like action) primarily stimulates intrasy-
naptic α1-adrenoceptors; (ii) i.v. bolus of exogenous
Fig. 5 Effects of i.p. pretreatment with vehicle (5% ascorbic acid) or
reserpine on the increases in: (a) heart rate (Δ Heart rate); and (b)
diastolic blood pressure (Δ DBP) produced by (R)-isometheptene
(0.03-3 mg/kg, i.v.) in pithed rats. *P < 0.05 vs. the corresponding
dose in the vehicle curve; n = 5 for each group
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noradrenaline mainly activates extrasynaptic α2-adreno-
ceptors; and (iii) systemic vascular resistance (represented
by diastolic blood pressure) is mainly modulated by
α1-adrenoceptors.
Interestingly, the fact that (R)-isometheptene-induced
tachycardic (Fig. 5a) and (weak) vasopressor (Fig. 5b)
responses were abolished by reserpine suggests the ex-
clusive role of a tyramine-like action in both responses
(with no role of direct sympathomimetic actions). This
implies that (R)-isometheptene would produce stoichio-
metric displacement of noradrenaline from the sympa-
thetic neurons innervating the heart and resistance
blood vessels, resulting in tachycardic and vasopressor
responses mediated by stimulation of cardiac β- and
vascular α1-adrenoceptors [3, 22, 23].
Structure of the enantiomers and stereo-specificity of the
α1-adrenoceptor
The different effects of the isometheptene enantiomers
on the cardiovascular system in this study could also be
explained by the chemical structures of these com-
pounds. Indeed, there are some similarities between the
molecular structures of isometheptene and noradren-
aline, which may confer the capability of being recog-
nized by the neuronal transporters, introduced into the
synaptic vesicles and subsequently displace the stored
catecholamines that, in turn, would interact with post-
junctional adrenoceptors. The presence of an amine side
chain in isometheptene provides the capability to stimu-
late directly the α1-adrenoceptor [23]. However, the
presence of a chiral centre in the β carbon of the amine
group could explain the differences in the pharmaco-
logical profile of both enantiomers, suggesting that (R)-
isometheptene cannot interact with the α1-adrenoceptor,
probably due to a steric impediment.
Study limitations
The pithed rat model is a useful preparation for investi-
gating the cardiovascular (side) effects of new developed
antimigraine drugs (i.e. isometheptene enantiomers) and
their mechanism of action. Since migraine-specific
agents, namely triptans, are contraindicated for acute
migraine attacks in patients with cardiovascular risk
factors, new antimigraine drugs should ideally have a
beneficial cardiovascular safety profile. The pithed rat
model is appropriate to assess peripheral cardiovascular
effects, however, it should be kept in mind that it
excludes central nervous system mechanisms, which
might be relevant in the clinical situation.
As migraine has a 2- to 3-fold higher prevalence in
women, another limitation of our study is that we used
only male rats. We deliberately chose to study male rats
in this case since we wanted to limit experimental
variation avoiding the effects of female hormones on
vascular responsiveness, as it is known that noradren-
aline vasopressor responses are altered in the presence
of 17β-estradiol in this model [24]. Thus, future studies
may focus on the antimigraine effects of the isomethep-
tene enantiomers in female models during different
hormonal cycle stages.
Conclusions
Our findings show that both isometheptene enantiomers
(R and S) are equipotent in producing tachycardic
responses, and that these responses are mediated by a
tyramine-like action (abolished by reserpine). Moreover,
(S)-isometheptene produced greater dose-dependent
vasopressor responses, while those produced by (R)-iso-
metheptene were not dose-dependent. These effects are
probably due to differences in their mechanism of
action, namely: (i) a mixed sympathomimetic action for
(S)-isometheptene (a tyramine-like action and a direct
stimulation of α1-adrenoceptors); and (ii) exclusively a
tyramine-like action for (R)-isometheptene.
Therefore, (R)-isometheptene may be responsible for the
therapeutic action of isometheptene racemate and (S)-iso-
metheptene (producing greater vasopressor responses)
might be associated with the vasospasm described with the
racemate. Accordingly, (R)-isometheptene may represent a
superior therapeutic benefit as an antimigraine agent.
Undoubtedly, further studies with (R)-isometheptene
in human preparations and in clinical studies will
shed further light on the potential role of imidazoline
receptors in the pathophysiology of migraine.
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